Join
Live feed
·
PRReleasevia Quantisnow
Kronos Bio Inc. logo

Kronos Bio To Present Interim Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1/2 KB-0742 Study at AACR-NCI-EORTC and Host Virtual Investor Event on October 13

ByQuantisnow·Wall Street's wire, on your screen.
KRON· Kronos Bio Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track KRON (Kronos Bio Inc.) and more on Quantisnow.